Document Detail

Complement anaphylatoxin C3a as a novel independent prognostic marker in heart failure.
MedLine Citation:
PMID:  22373875     Owner:  NLM     Status:  Publisher    
OBJECTIVES: The purpose of this study was to evaluate complement activation in a heart failure cohort. Based on their powerful biological activity, we hypothesized that the levels of anaphylatoxin C3a are related to pathological signs and outcomes in heart failure. DESIGN, SETTING AND PATIENTS: Complement activation products C3a and SC5b9 were determined in 182 consecutive CHF patients (single centre, prospective cohort study), with a left ventricular ejection fraction <45%. Mortality and re-hospitalisation due to the progression of CHF were assessed after a median follow-up of 14 months. INTERVENTIONS: None. RESULTS: In the univariate analysis, high level of anaphylatoxin C3a was significantly associated with clinical events (p < 0.0001), whereas SC5b9 showed a tendency of association (p = 0.094). In multivariable Cox analysis, adjusted for age, NT-proBNP, diastolic blood pressure, body mass index (BMI), haemoglobin and creatinine levels, C3a was a significant predictor of HF-related re-hospitalization or death (HR 1.189 per 1-SD increase, 95% CI 1.023-1.383), and of cardiovascular events or death (HR 1.302, CI 1.083-1.566). C3a was strongly associated with the presence of peripheral oedema, inflammatory markers (CRP, prealbumin, IL-6, sTNFRI, sTNFRII), heat-shock protein 70 levels and endothelial activation markers (von-Willebrand factor and endothelin-1). CONCLUSIONS: Results of the present study showed that complement activation is strongly linked to unfavourable outcomes in heart failure. High levels of anaphylatoxin C3a predicted re-hospitalization, cardiovascular events and mortality in adjusted survival model. Increased C3a levels were associated with biomarkers of acute-phase reaction, inflammation, cellular stress response, endothelial-cell activation and oedematous complications independently from disease severity.
Tímea Gombos; Zsolt Förhécz; Zoltán Pozsonyi; Gábor Széplaki; Jan Kunde; George Füst; Lívia Jánoskuti; István Karádi; Zoltán Prohászka
Related Documents :
21783125 - Active contraction of cardiac muscle: in vivo characterization of mechanical activation...
16970725 - Live/real time three-dimensional echocardiographic demonstration of left ventricular no...
22075545 - Atrial fibrillation (chronic).
22528555 - Baroreflex activation for the treatment of heart failure.
22766115 - Assessment of right ventricular function in recipient twin of twin to twin transfusion ...
12718735 - Screening for treatable left ventricular abnormalities in diabetic patients.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-2-29
Journal Detail:
Title:  Clinical research in cardiology : official journal of the German Cardiac Society     Volume:  -     ISSN:  1861-0692     ISO Abbreviation:  -     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-2-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101264123     Medline TA:  Clin Res Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
IIIrd Department of Internal Medicine, Semmelweis University, Kútvölgyi út 4, Budapest, 1125, Hungary.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Secreted miRNAs suppress atherogenesis.
Next Document:  Preferential growth of short aligned, metallic-rich single-walled carbon nanotubes from perpendicula...